Peer support for patients with type 2 diabetes in rural communities of China: protocol for a cluster randomized controlled trial

BMC Public Health

Yanxiaoxiao Yang²  Carvalho Husni Da Costa De Vladmir²  Li Yao²  Chang-ping Ju²  Hui Jin¹  Min Jia²  Zi-lin Sun²  Xiu-li Ye²  Bo Xie² 

[1] Department of Epidemiology and Health Statistics, Southeast University, Nanjing 210009, China;Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, Medical School, Southeast University, Nanjing 210009, China

关键词: Rural health;    Self-management;    Diabetes;    Peer support;   

Others  :  1128946
DOI  :  10.1186/1471-2458-14-747

 received in 2014-05-31, accepted in 2014-07-16,  发布年份 2014

【 摘 要 】

Background

The prevalence of diabetes has been growing rapidly in developing countries. This causes devastating economic burdens and increases demands on the health care system. Therefore, there is an urgent need to find a cost-effective and multi-faceted approach for diabetes care. Peer support models provide a potentially low-cost, flexible means which complements the current existing health care services. In this way, trained peer leaders can become qualified extensions to a formal healthcare system, capable of assisting education delivery and bolstering the efforts of professional staff. As such, creating a cultural specific peer support program and determining whether it is acceptable and cost-effective in rural communities of China is crucial. This study aims to implement and evaluate biophysical and psychosocial outcomes of peer support program for people with type 2 diabetes in rural communities, and to explore the program’s feasibility and sustainability in China.

Methods/Design

This study is a cluster randomised controlled trial. All consenting patients will be randomised by community staff members to receive either peer support or the control care. The data collection and analysis including social demographics, health status, psychosocial status, economic status and biomedical measures will be collected at baseline, 6 months, and 12 months. The primary indicator measured is the change in HbA1c, whereas secondary indicators include biophysical, psychosocial functioning and other lifestyle factors. Finally, economic evaluations will determine whether the program is cost effective.

Discussion

This protocol is a cluster randomized, controlled trial of group-based peer support for people with type 2 diabetes in the community settings of rural China. Results from this trial may provide evidence to the effectiveness of peer support; furthermore, they will provide valuable information concerning the acceptability and feasibility of a new approach to improve diabetes self-management among resource-constrained settings.

Trial registration

ClinicalTrials.gov Identifier: NCT02119572, April 18, 2014.

【 授权许可】

   
2014 Xie et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014, 103(2):137-149.
• [2]Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G: Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87(3):293-301.
• [3]Zabetian A, Sanchez IM, Narayan KM, Hwang CK, Ali MK: Global rural diabetes prevalence: A systematic review and meta-analysis covering 1990–2012. Diabetes Res Clin Pract 2014, 104(2):206-213.
• [4]Routasalo PE, Savikko N, Tilvis RS, Strandberg TE, Pitkala KH: Social contacts and their relationship to loneliness among aged people - a population-based study. Gerontology 2006, 52(3):181-187.
• [5]Ghorob A, Vivas MM, De Vore D, Ngo V, Bodenheimer T, Chen E, Thom DH: The effectiveness of peer health coaching in improving glycemic control among low-income patients with diabetes: protocol for a randomized controlled trial. BMC Public Health 2011, 11:208. BioMed Central Full Text
• [6]Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G, 2010 China Noncommunicable Disease Surveillance Group: Prevalence and control of diabetes in Chinese adults. JAMA 2013, 310(9):948-959.
• [7]Shen H, Edwards H, Courtney M, McDowell J, Wu M: Peer-led diabetes self-management programme for community-dwelling older people in China: study protocol for a quasi-experimental design. J Adv Nurs 2012, 68(12):2766-2777.
• [8]Dennis C-L: Peer support within a health care context: a concept analysis. Int J Nurs Stud 2003, 40(3):321-332.
• [9]Boothroyd RI, Fisher EB: Peers for progress: promoting peer support for health around the world. Fam Pract 2010, 27(Suppl 1):i62-i68.
• [10]Dale JR, Williams SM, Bowyer V: What is the effect of peer support on diabetes outcomes in adults? A systematic review. Diabet Med 2012, 29(11):1361-1377.
• [11]Heisler M: Different models to mobilize peer support to improve diabetes self-management and clinical outcomes: evidence, logistics, evaluation considerations and needs for future research. Fam Pract 2010, 27(Suppl 1):i23-i32.
• [12]Sylvia S, Shi Y, Xue H, Tian X, Wang H, Liu Q, Medina A, Rozelle S: Survey using incognito standardized patients shows poor quality care in China’s rural clinics. Health Policy Plan 2014. [Epub ahead of print]
• [13]Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG: CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340(mar23 1):c869-c879.
• [14]Campbell MK, Piaggio G, Elbourne DR, Altman DG: Consort 2010 statement: extension to cluster randomised trials. BMJ 2012, 345(sep04 1):e5661-e5671.
• [15]Toobert DJ, Hampson SE, Glasgow RE: The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care 2000, 23(7):943-950.
• [16]Lorig K, Ritter PL, Villa FJ, Armas J: Community-based peer-led diabetes self-management: a randomized trial. Diabetes Educ 2009, 35(4):641-651.
• [17]Morisky DE, Ang A, Krousel-Wood M, Ward HJ: Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 2008, 10(5):348-354.
• [18]Morisky DE, Green LW, Levine DM: Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24(1):67-74.
• [19]Koltowska-Haggstrom M, Jonsson B, Isacson D, Bingefors K: Using EQ-5D to derive general population-based utilities for the quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA). Value Health 2007, 10(1):73-81.
• [20]Wang HM, Patrick DL, Edwards TC, Skalicky AM, Zeng HY, Gu WW: Validation of the EQ-5D in a general population sample in urban China. Qual Life Res 2012, 21(1):155-160.
• [21]EuroQol Group: EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990, 16(3):199-208.
• [22]Fisher L, Glasgow RE, Mullan JT, Skaff MM, Polonsky WH: Development of a brief diabetes distress screening instrument. Ann Fam Med 2008, 6(3):246-252.
• [23]Polonsky WH, Fisher L, Earles J, Dudl RJ, Lees J, Mullan J, Jackson RA: Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care 2005, 28(3):626-631.
• [24]Thompson ER: Development and validation of an internationally reliable short-form of the Positive and Negative Affect Schedule (PANAS). J Cross Cult Gerontol 2007, 38(2):227-242.
• [25]Diener E, Emmons RA, Larsen RJ, Griffin S: The Satisfaction With Life Scale. J Pers Assess 1985, 49(1):71-75.
• [26]Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16(9):606-613.
• [27]Lovibond PF, Lovibond SH: The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther 1995, 33(3):335-343.
• [28]Chan RC, Xu T, Huang J, Wang Y, Zhao Q, Shum DH, O’Gorman J, Potangaroa R: Extending the utility of the Depression Anxiety Stress scale by examining its psychometric properties in Chinese settings. Psychiatry Res 2012, 200(2–3):879-883.
• [29]The WHO STEPwise approach to surveillance (STEPS) [http://www.who.int/chp/steps/en/ webcite]
• [30]Hadden DR, Savage GA, Lappin TR, Elder GE: What is the gold standard for glycosylated haemoglobin? Lancet 1993, 342(8884):1424-1425.
• [31]Peters AL, Davidson MB, Schriger DL, Hasselblad V: A clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. JAMA 1996, 276(15):1246-1252.
• [32]Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991, 325(12):836-842.
• [33]Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318(20):1315-1321.
• [34]Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ: The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006, 15(10):1121-1132.
• [35]World Health Organization: 2008-2013 action plan for the global strategy for the prevention and control of noncommunicable diseases. Geneva: World Health Organization; 2009.
• [36]Amer Diabet A: Standards of medical care in diabetes-2011 American Diabetes Association. Diabetes Care 2011, 34:S11-S61.